Overview An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894 Status: RECRUITING Trial end date: 2027-11-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).Phase: PHASE2 Details Lead Sponsor: Crinetics Pharmaceuticals Inc.